Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Personalis, Inc. - Common Stock (NQ:PSNL)

7.970 +0.040 (+0.50%)
Streaming Delayed Price Updated: 4:00 PM EST, Dec 30, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Personalis, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
News headline image
Nasdaq Jumps Over 300 Points, Novo Nordisk Shares Spike Higher ↗
 
Via Benzinga
News headline image
Mission Produce, Nvidia, Humacyte, BlackBerry And Other Big Stocks Moving Higher On Friday ↗
 
Via Benzinga
News headline image
Stock Of The Day: Where Does The Merck Downtrend End? ↗
Shares of Merck & Co (MRK) continue to trend lower. If they reach the $95.00 level, there is a good chance they find support and reverse. 
Via Benzinga
News headline image
Personalis Advances Business Strategy with Investment from Merck and Extends Collaboration with Moderna
From Personalis, Inc.
Via Business Wire
News headline image
Key Takeaways From Personalis Analyst Ratings ↗
 
Via Benzinga
News headline image
What Analysts Are Saying About Personalis Stock ↗
 
Via Benzinga
News headline image
Assessing Personalis: Insights From 4 Financial Analysts ↗
 
Via Benzinga
News headline image
Personalis and Tempus Expand Collaboration to Biopharma
From Personalis, Inc.
Via Business Wire
News headline image
Personalis to Participate at Upcoming Investor Conferences
From Personalis, Inc.
Via Business Wire
News headline image
12 Health Care Stocks Moving In Thursday's Intraday Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Breaking Down Personalis: 4 Analysts Share Their Views ↗
 
Via Benzinga
News headline image
Personalis Reports Third Quarter 2024 Financial Results
From Personalis, Inc.
Via Business Wire
News headline image
Personalis to Present at the Stifel 2024 Healthcare Conference
From Personalis, Inc.
Via Business Wire
News headline image
Personalis to Announce Third Quarter 2024 Financial Results
From Personalis, Inc.
Via Business Wire
News headline image
ESMO 2024 Data Expands on Compelling Performance of Personalis NeXT Personal® MRD Test
From Personalis, Inc.
Via Business Wire
News headline image
Biotech Stock Soars 60% in 2024: Cathie Wood’s Bold Investment
Tempus AI is a hot healthcare stock that investors should be aware of. It is using AI to pursue "precision medicine", especially in cancer research. 
Via MarketBeat
Topics Artificial Intelligence ETFs
News headline image
Personalis to Participate at Upcoming Investor Conferences
From Personalis, Inc.
Via Business Wire
News headline image
Why Tempus AI Stock Skyrocketed Nearly 22% Today ↗
It deepened its involvement in a client and peer. 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
Personalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Personalis, Inc.
Via Business Wire
News headline image
Personalis and Tempus Announce Expanded Collaboration
From Personalis, Inc.
Via Business Wire
News headline image
PSNL Stock Earnings: Personalis Beats EPS, Beats Revenue for Q2 2024 ↗
PSNL stock results show that Personalis beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. 
Via InvestorPlace
News headline image
Personalis Reports Second Quarter 2024 Financial Results
From Personalis, Inc.
Via Business Wire
News headline image
Myriad Genetics Reports Strong Second Quarter 2024 Financial Results, including 15% Revenue Growth Year-Over-Year; Raises 2024 Financial Guidance and Long-Term Revenue Growth Target to 12%
From Myriad Genetics, Inc.
Via GlobeNewswire
News headline image
Personalis to Participate at the 9th Annual Needham Virtual MedTech & Diagnostics 1x1 Conference
From Personalis, Inc.
Via Business Wire
News headline image
Personalis to Announce Second Quarter 2024 Financial Results
From Personalis, Inc.
Via Business Wire
News headline image
Myriad Genetics and Personalis Cross-License Foundational MRD Intellectual Property to Broaden Patient Access to Testing
From Myriad Genetics, Inc.
Via GlobeNewswire
News headline image
Personalis to Participate at the TD Cowen 3rd Annual Tools / Dx Revolution Conference
From Personalis, Inc.
Via Business Wire
News headline image
Personalis Provides Dial-in and Updated Date for ASCO Highlights Conference Call
From Personalis, Inc.
Via Business Wire
News headline image
ASCO Data Highlights NeXT Personal® Ultra-sensitive MRD Performance in Early-stage Breast Cancer Recurrence Detection and Immunotherapy Monitoring
From Personalis, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.